Invasive breast cancer occurs when abnormal cells spread into the surrounding breast tissue.. In 1997 , the FDA approved Evista for the prevention of osteoporosis in postmenopausal women and in 1999 for the treatment of postmenopausal women with osteoporosis.Breast cancer is the second leading cause of cancer death in American women and accounts for 26 % of all cancers in women. An estimated 178,480 new cases of invasive breast cancer are expected to occur among women in the United States in 2007.
‘Today’s action provides an important new option for women at increased risk of breast cancer,’said Steven Galson, Director, FDA Center for Drug Evaluation and Research. ‘Because Evista can cause serious side effects, should the benefits and risks of taking Evista be carefully evaluated for each individual woman. Women should talk with their doctor about whether the drug is right for them. ‘.But some of tell progress has raised exponential in the last five years, thanks a greater understanding of tumor biology, from the development of a targeted that can extend that can extend survival in specific susceptible patient led.